Business
Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Advanced research and development of CUE-401 for IND (Investigational New Drug) readiness –CUE-401 is the Company’s lead asset for the treatment of autoimmune and inflammatory diseasesAppointed industry veteran Lucinda Warren as Chief Financial and Business OfficerRaised net proceeds of $10.2M through an underwritten public offeringAnnounced strategic collaboration and license agreement with ImmunoScape to develop breakthrough cell therapy approach for solid tumors – Entitled to receive upfront
About this update from Cue Biopharma, Inc.
[{"type":"image","alt":"Cue Biopharma, Inc.","displaySize":"","headline":null,"caption":"Cue Biopharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":110,"url":"https://media.zenfs.com/en/globenewswire.com/2e66156a6e123e96f63fe86db58bbe09"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/btk.uQvFNhbkAb9kiEpvZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2e66156a6e123e96f63fe86db58bbe09","width":300,"height":110}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Advanced research and development of CUE-401 for IND (Investigational New Drug) readiness –CUE-401 is the Company’s lead asset for the treatment of autoimmune and inflammatory diseases","length":185,"tagName":"p"}]},{"val":[{"type":"text","content":"Appointed industry veteran Lucinda Warren as Chief Financial and Business Officer","length":81,"tagName":"p"}]},{"val":[{"type":"text","content":"Raised net proceeds of $10.2M through an underwritten public offering","length":69,"tagName":"p"}]},{"val":[{"type":"text","content":"Announced strategic collaboration and license agreement with ImmunoScape to develop breakthrough cell therapy approach for solid tumors – Entitled to receive upfront payments totaling $15M","length":188,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":523,"olType":false},{"type":"text","content":"BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today reported fourth quarter and full year 2025 financial results.","length":362,"tagName":"p"},{"type":"text","content":"“During the fourth quarter and throughout the full year 2025, the Company successfully met its strategic development goals and objectives that demonstrated significant progress towards establishing potential first-in-class and best-in-class assets for patients suffering with autoimmune diseases,” said Usman Azam, M.D., president and chief executive officer of Cue Biopharma. “With these strategic deliverables and continued progress to date, we believe we are well positioned to further advance our differentiating Immuno-STAT® plat...